Jan 10 (Reuters) - Royalty Pharma ( RPRX ) said on
Friday it would pay about $1.1 billion to acquire RP Management,
an organization that manages its operations as the healthcare
firm seeks to simplify corporate structure.
Royalty Pharma ( RPRX ) buys royalties of future drugs from academic
labs and biotechnology companies, which in turn use the cash to
fund their research.